189 related articles for article (PubMed ID: 33597926)
1. Switching From Immediate-Release to Fractionated Dual-Release Hydrocortisone May Improve Metabolic Control and QoL in Selected Primary Adrenal Insufficiency Patients.
Delle Cese F; Corsello A; Cintoni M; Locantore P; Pontecorvi A; Corsello SM; Paragliola RM
Front Endocrinol (Lausanne); 2020; 11():610904. PubMed ID: 33597926
[TBL] [Abstract][Full Text] [Related]
2. Cardiometabolic and psychological effects of dual-release hydrocortisone: a cross-over study.
Dineen R; Martin-Grace J; Ahmed KMS; Frizelle I; Gunness A; Garrahy A; Hannon AM; O'Reilly MW; Smith D; McDermott J; Healy ML; Agha A; Pazderska A; Gibney J; Thompson CJ; Behan LA; Sherlock M
Eur J Endocrinol; 2021 Feb; 184(2):253-265. PubMed ID: 33513125
[TBL] [Abstract][Full Text] [Related]
3. Modified-release hydrocortisone decreases BMI and HbA1c in patients with primary and secondary adrenal insufficiency.
Quinkler M; Miodini Nilsen R; Zopf K; Ventz M; Øksnes M
Eur J Endocrinol; 2015 May; 172(5):619-26. PubMed ID: 25656494
[TBL] [Abstract][Full Text] [Related]
4. Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): a single-blind, randomised controlled trial.
Isidori AM; Venneri MA; Graziadio C; Simeoli C; Fiore D; Hasenmajer V; Sbardella E; Gianfrilli D; Pozza C; Pasqualetti P; Morrone S; Santoni A; Naro F; Colao A; Pivonello R; Lenzi A
Lancet Diabetes Endocrinol; 2018 Mar; 6(3):173-185. PubMed ID: 29229498
[TBL] [Abstract][Full Text] [Related]
5. Benefits of dual-release hydrocortisone treatment on central adiposity and health-related quality of life in secondary adrenal insufficiency.
Gasco V; Giannelli J; Campioni L; Arvat E; Ghigo E; Grottoli S; Maccario M; Giordano R
J Endocrinol Invest; 2023 Mar; 46(3):587-597. PubMed ID: 36251244
[TBL] [Abstract][Full Text] [Related]
6. Prospective evaluation of long-term safety of dual-release hydrocortisone replacement administered once daily in patients with adrenal insufficiency.
Nilsson AG; Marelli C; Fitts D; Bergthorsdottir R; Burman P; Dahlqvist P; Ekman B; Engström BE; Olsson T; Ragnarsson O; Ryberg M; Wahlberg J; Lennernäs H; Skrtic S; Johannsson G
Eur J Endocrinol; 2014 Sep; 171(3):369-77. PubMed ID: 24944332
[TBL] [Abstract][Full Text] [Related]
7. Achieving a physiological cortisol profile with once-daily dual-release hydrocortisone: a pharmacokinetic study.
Johannsson G; Lennernäs H; Marelli C; Rockich K; Skrtic S
Eur J Endocrinol; 2016 Jul; 175(1):85-93. PubMed ID: 27129362
[TBL] [Abstract][Full Text] [Related]
8. Dual-release hydrocortisone and its benefits on cognitive function and quality of sleep.
Krekeler C; Kropp P; Blacha AK; Rahvar AH; Harbeck B
Endocrine; 2021 Apr; 72(1):223-233. PubMed ID: 33625720
[TBL] [Abstract][Full Text] [Related]
9. Improved Urinary Cortisol Metabolome in Addison Disease: A Prospective Trial of Dual-Release Hydrocortisone.
Espiard S; McQueen J; Sherlock M; Ragnarsson O; Bergthorsdottir R; Burman P; Dahlqvist P; Ekman B; Engström BE; Skrtic S; Wahlberg J; Stewart PM; Johannsson G
J Clin Endocrinol Metab; 2021 Mar; 106(3):814-825. PubMed ID: 33236103
[TBL] [Abstract][Full Text] [Related]
10. Influence of hydrocortisone dosage scheme on health-related quality of life in patients with adrenal insufficiency.
Bleicken B; Hahner S; Loeffler M; Ventz M; Decker O; Allolio B; Quinkler M
Clin Endocrinol (Oxf); 2010 Mar; 72(3):297-304. PubMed ID: 19508599
[TBL] [Abstract][Full Text] [Related]
11. Tissue Glucocorticoid Metabolism in Adrenal Insufficiency: A Prospective Study of Dual-release Hydrocortisone Therapy.
Dineen RA; Martin-Grace J; Ahmed KMS; Taylor AE; Shaheen F; Schiffer L; Gilligan LC; Lavery GG; Frizelle I; Gunness A; Garrahy A; Hannon AM; Methlie P; Eystein SH; Stewart PM; Tomlinson JW; Hawley JM; Keevil BG; O'Reilly MW; Smith D; McDermott J; Healy ML; Agha A; Pazderska A; Gibney J; Behan LA; Thompson CJ; Arlt W; Sherlock M
J Clin Endocrinol Metab; 2023 Nov; 108(12):3178-3189. PubMed ID: 37339332
[TBL] [Abstract][Full Text] [Related]
12. GLUCOCORTICOID REPLACEMENT REGIMENS IN CHRONIC ADRENAL INSUFFICIENCY: A SYSTEMATIC REVIEW AND META-ANALYSIS.
Al Nofal A; Bancos I; Benkhadra K; Ospina NM; Javed A; Kapoor E; Muthusamy K; Brito JP; Turcu AF; Wang Z; Prokop L; Erickson DZ; Lteif AN; Natt N; Murad MH
Endocr Pract; 2017 Jan; 23(1):17-31. PubMed ID: 27631672
[TBL] [Abstract][Full Text] [Related]
13. Early Metabolic Benefits of Switching Hydrocortisone to Modified Release Hydrocortisone in Adult Adrenal Insufficiency.
Bannon CAM; Border D; Hanson P; Hattersley J; Weickert MO; Grossman A; Randeva HS; Barber TM
Front Endocrinol (Lausanne); 2021; 12():641247. PubMed ID: 33776936
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind, crossover study comparing two- and four-dose hydrocortisone regimen with regard to quality of life, cortisol and ACTH profiles in patients with primary adrenal insufficiency.
Ekman B; Bachrach-Lindström M; Lindström T; Wahlberg J; Blomgren J; Arnqvist HJ
Clin Endocrinol (Oxf); 2012 Jul; 77(1):18-25. PubMed ID: 22288685
[TBL] [Abstract][Full Text] [Related]
15. Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation.
Johannsson G; Nilsson AG; Bergthorsdottir R; Burman P; Dahlqvist P; Ekman B; Engström BE; Olsson T; Ragnarsson O; Ryberg M; Wahlberg J; Biller BM; Monson JP; Stewart PM; Lennernäs H; Skrtic S
J Clin Endocrinol Metab; 2012 Feb; 97(2):473-81. PubMed ID: 22112807
[TBL] [Abstract][Full Text] [Related]
16. Long-term safety of once-daily, dual-release hydrocortisone in patients with adrenal insufficiency: a phase 3b, open-label, extension study.
Nilsson AG; Bergthorsdottir R; Burman P; Dahlqvist P; Ekman B; Engström BE; Ragnarsson O; Skrtic S; Wahlberg J; Achenbach H; Uddin S; Marelli C; Johannsson G
Eur J Endocrinol; 2017 Jun; 176(6):715-725. PubMed ID: 28292927
[TBL] [Abstract][Full Text] [Related]
17. Dual-release hydrocortisone vs conventional glucocorticoids in adrenal insufficiency.
Guarnotta V; Di Stefano C; Santoro A; Ciresi A; Coppola A; Giordano C
Endocr Connect; 2019 Jul; 8(7):853-862. PubMed ID: 31252397
[TBL] [Abstract][Full Text] [Related]
18. A pharmacokinetic and pharmacodynamic study of delayed- and extended-release hydrocortisone (Chronocort) vs. conventional hydrocortisone (Cortef) in the treatment of congenital adrenal hyperplasia.
Verma S; Vanryzin C; Sinaii N; Kim MS; Nieman LK; Ravindran S; Calis KA; Arlt W; Ross RJ; Merke DP
Clin Endocrinol (Oxf); 2010 Apr; 72(4):441-7. PubMed ID: 19486026
[TBL] [Abstract][Full Text] [Related]
19. Improvement of anthropometric and metabolic parameters, and quality of life following treatment with dual-release hydrocortisone in patients with Addison's disease.
Giordano R; Guaraldi F; Marinazzo E; Fumarola F; Rampino A; Berardelli R; Karamouzis I; Lucchiari M; Manetta T; Mengozzi G; Arvat E; Ghigo E
Endocrine; 2016 Feb; 51(2):360-8. PubMed ID: 26184416
[TBL] [Abstract][Full Text] [Related]
20. Use of dual-release hydrocortisone in adrenal insufficiency.
Patra S; Roy A; Mittal M; Shukla R
Eur J Endocrinol; 2021 Aug; 185(3):L9-L10. PubMed ID: 34243144
[No Abstract] [Full Text] [Related]
[Next] [New Search]
